Rapport Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-09-18. 4 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Third Rock Ventures V, L.P. | 13.1% | 6,280,525 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Capital International Investors | 6.1% | 2,921,958 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Cormorant Asset Management, LP | 5.56% | 2,657,521 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 5.03% | 2,397,549 | SCHEDULE 13G, 2026-01-21 | 2025-12-31 |
| Johnson & Johnson | 4.9% | 1,784,517 | SCHEDULE 13G/A, 2025-10-22 | 2025-09-30 |
| Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.2% | 1,863,327 | SCHEDULE 13D/A, 2025-09-18 | 2025-09-11 |
Purpose of Transaction (Item 4)
Sofinnova Venture Partners XI, L.P. ("SVP XI")
The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2025-09-18
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-18 | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.2% | SCHEDULE 13D/A |
| 2025-10-22 | Johnson & Johnson | 4.9% | SCHEDULE 13G/A |
| 2025-11-14 | Cormorant Asset Management, LP | 6.7% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 5.03% | SCHEDULE 13G |
| 2026-02-17 | Cormorant Asset Management, LP | 6.35% | SCHEDULE 13G/A |
| 2026-05-15 | Cormorant Asset Management, LP | 6.19% | SCHEDULE 13G/A |
| 2026-08-12 | Capital International Investors | 6.1% | SCHEDULE 13G/A |
| 2026-08-14 | Cormorant Asset Management, LP | 5.56% | SCHEDULE 13G/A |
| 2026-08-14 | Third Rock Ventures V, L.P. | 13.1% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Rapport Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.